GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » Cash per Share

enGene Holdings (enGene Holdings) Cash per Share : $3.69 (As of Jan. 2024)


View and export this data going back to 2023. Start your Free Trial

What is enGene Holdings Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). enGene Holdings's Cash per Share for the quarter that ended in Jan. 2024 was $3.69.

enGene Holdings Cash per Share Historical Data

The historical data trend for enGene Holdings's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enGene Holdings Cash per Share Chart

enGene Holdings Annual Data
Trend Oct20 Oct21 Oct22 Oct23
Cash per Share
- 0.48 0.88 3.51

enGene Holdings Quarterly Data
Oct20 Oct21 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.75 1.62 3.51 3.69

enGene Holdings Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

enGene Holdings's Cash per Share for the fiscal year that ended in Oct. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=81.521/23.20
=3.51

enGene Holdings's Cash per Share for the quarter that ended in Jan. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=85.646/23.20
=3.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enGene Holdings  (NAS:ENGN) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

enGene Holdings Cash per Share Related Terms

Thank you for viewing the detailed overview of enGene Holdings's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

enGene Holdings (enGene Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » Cash per Share
Comparable Companies
Traded in Other Exchanges
N/A
Address
7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9
Website
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Executives
Richard M Glickman director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jason David Hanson director, officer: Chief Executive Officer 8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Richard Paul Bryce officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Fonds De Solidarite Des Travailleurs Du Quebec 10 percent owner 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Gerald A Brunk director C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142
Jasper Bos director BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102
Grassin Alexandre Jean-rene Erwan officer: Int. Chief Financial Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Anthony Tzeyew Cheung officer: Chief Technology Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Alexander Julian Nichols officer: Pres. & Chief Operating Ofc. 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
James Crowley Sullivan officer: Chief Scientific Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Forbion Growth Sponsor Feac I B.v. 10 percent owner GOOIMEER 2 35,, NAARDEN P7 1411DC
Forbion Growth Opportunities Fund I Cooperatief U.a. 10 percent owner GOOIMEER 235, 1411 DC, NAARDEN P7 00000
Forbion Growth Management B.v. 10 percent owner C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807

enGene Holdings (enGene Holdings) Headlines

From GuruFocus

enGene Appoints Ryan Daws as Chief Financial Officer

By PRNewswire • 11-29-2023

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

By PRNewswire • 12-19-2023

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

By PRNewswire • 12-22-2023